← Back to Screener
Harmony Biosciences Holdings, Inc. Common Stock (HRMY)
Price$29.53
Favorite Metrics
Price vs S&P 500 (26W)4.25%
Price vs S&P 500 (4W)-1.30%
Market Capitalization$1.73B
P/E Ratio (Annual)10.93x
All Metrics
P/CF (Annual)4.98x
Book Value / Share (Quarterly)$15.07
P/TBV (Annual)2.76x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)25.64%
Cash Flow / Share (Quarterly)$5.69
Price vs S&P 500 (YTD)-23.99%
Gross Margin (TTM)77.16%
Net Profit Margin (TTM)18.27%
EPS (TTM)$2.71
10-Day Avg Trading Volume0.61M
EPS Excl Extra (TTM)$2.71
Revenue Growth (5Y)40.31%
EPS (Annual)$2.71
ROI (Annual)15.35%
Gross Margin (Annual)77.16%
Net Profit Margin (5Y Avg)22.71%
Cash / Share (Quarterly)$13.43
P/E Basic Excl Extra (TTM)10.93x
Revenue Growth QoQ (YoY)21.12%
P/E Normalized (Annual)10.93x
ROA (Last FY)12.48%
Revenue Growth TTM (YoY)21.51%
EBITD / Share (TTM)$3.97
ROE (5Y Avg)26.30%
Operating Margin (TTM)24.00%
Cash Flow / Share (Annual)$5.69
P/B Ratio1.99x
P/B Ratio (Quarterly)2.48x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)1.32x
Net Interest Coverage (TTM)20.21x
ROA (TTM)13.67%
EPS Growth QoQ (YoY)-54.35%
EV / EBITDA (TTM)4.95x
EPS Incl Extra (Annual)$2.71
Current Ratio (Annual)3.60x
Quick Ratio (Quarterly)3.51x
3-Month Avg Trading Volume0.81M
52-Week Price Return7.34%
EV / Free Cash Flow (Annual)3.49x
P/E Incl Extra (TTM)10.93x
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$13.53
P/S Ratio (Annual)2.00x
Asset Turnover (Annual)0.68x
52-Week High$40.87
Operating Margin (5Y Avg)25.91%
EPS Excl Extra (Annual)$2.71
CapEx CAGR (5Y)-56.63%
26-Week Price Return13.00%
Quick Ratio (Annual)3.51x
13-Week Price Return-16.79%
Total Debt / Equity (Annual)0.19x
Current Ratio (Quarterly)3.60x
Enterprise Value$1,145.801
Revenue / Share Growth (5Y)39.51%
Asset Turnover (TTM)0.75x
Book Value / Share Growth (5Y)54.57%
Revenue / Employee (Annual)$3
Inventory Turnover (Annual)31.60x
Pretax Margin (Annual)24.76%
Cash / Share (Annual)$13.43
3-Month Return Std Dev44.83%
Gross Margin (5Y Avg)79.43%
Net Income / Employee (TTM)$1
EBITDA Interim CAGR (5Y)41.25%
ROE (Last FY)18.24%
Net Interest Coverage (Annual)29.83x
EPS Basic Excl Extra (Annual)$2.71
P/FCF (TTM)5.28x
Receivables Turnover (TTM)9.66x
EV / Free Cash Flow (TTM)3.49x
Total Debt / Equity (Quarterly)0.19x
EPS Incl Extra (TTM)$2.71
Receivables Turnover (Annual)9.66x
ROI (TTM)16.36%
P/S Ratio (TTM)2.00x
Pretax Margin (5Y Avg)23.51%
Revenue / Share (Annual)$14.83
Tangible BV / Share (Annual)$13.53
Forward P/E8.35x
Price vs S&P 500 (52W)-27.76%
P/E Ratio (TTM)10.93x
EPS Growth TTM (YoY)8.31%
Year-to-Date Return-19.86%
5-Day Price Return3.24%
EPS Normalized (Annual)$2.71
ROA (5Y Avg)15.57%
Net Profit Margin (Annual)18.27%
Month-to-Date Return7.07%
Cash Flow / Share (TTM)$2.87
EBITD / Share (Annual)$3.96
EPS Growth (3Y)-3.01%
Operating Margin (Annual)24.00%
LT Debt / Equity (Annual)0.17x
P/CF (TTM)4.98x
ROI (5Y Avg)18.38%
P/E Excl Extra (TTM)10.93x
LT Debt / Equity (Quarterly)0.17x
EPS Basic Excl Extra (TTM)$2.71
P/TBV (Quarterly)2.76x
P/B Ratio (Annual)2.48x
Inventory Turnover (TTM)31.60x
Pretax Margin (TTM)24.76%
Book Value / Share (Annual)$15.07
Price vs S&P 500 (13W)-19.65%
Beta0.95x
P/FCF (Annual)5.28x
Revenue / Share (TTM)$14.98
ROE (TTM)19.84%
52-Week Low$25.52
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.94
3.94
3.76
3.76
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
HRMYHarmony Biosciences Holdings, Inc. Common Stock | 2.00x | 21.51% | 77.16% | — | $29.53 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Harmony Biosciences is a pharmaceutical company commercializing therapies for rare neurological diseases with unmet medical needs. Its approved product WAKIX (pitolisant) treats cataplexy in narcolepsy patients through a novel H3 receptor mechanism. The company has multiple pipeline candidates targeting additional rare neurological conditions, positioning it in a specialized and underserved market segment.